HY-10015-10mg
|
MedChemexpress LLC
|
PAP-1 [CAS 870653-45-5]
|
|
COVID-19-immunoregulation
|
|
HY-10015-100mg
|
MedChemexpress LLC
|
PAP-1 [CAS 870653-45-5]
|
|
COVID-19-immunoregulation
|
|
HY-10015-25mg
|
MedChemexpress LLC
|
PAP-1 [CAS 870653-45-5]
|
|
COVID-19-immunoregulation
|
|
HY-10015-5mg
|
MedChemexpress LLC
|
PAP-1 [CAS 870653-45-5]
|
|
COVID-19-immunoregulation
|
|
HY-10015-50mg
|
MedChemexpress LLC
|
PAP-1 [CAS 870653-45-5]
|
|
COVID-19-immunoregulation
|
|
HY-103332-10mg
|
MedChemexpress LLC
|
N-Arachidonylglycine [CAS 179113-91-8]
|
|
COVID-19-immunoregulation
|
|
HY-103332-100mg
|
MedChemexpress LLC
|
N-Arachidonylglycine [CAS 179113-91-8]
|
|
COVID-19-immunoregulation
|
|
HY-103332-25mg
|
MedChemexpress LLC
|
N-Arachidonylglycine [CAS 179113-91-8]
|
|
COVID-19-immunoregulation
|
|
HY-103332-5mg
|
MedChemexpress LLC
|
N-Arachidonylglycine [CAS 179113-91-8]
|
|
COVID-19-immunoregulation
|
|
HY-103332-50mg
|
MedChemexpress LLC
|
N-Arachidonylglycine [CAS 179113-91-8]
|
|
COVID-19-immunoregulation
|
|
HY-103637A-1mg
|
MedChemexpress LLC
|
Vimirogant (hydrochloride) [CAS 1802678-42-7]
|
|
COVID-19-immunoregulation
|
|
HY-103637A-10mg
|
MedChemexpress LLC
|
Vimirogant (hydrochloride) [CAS 1802678-42-7]
|
|
COVID-19-immunoregulation
|
|
HY-103637A-5mg
|
MedChemexpress LLC
|
Vimirogant (hydrochloride) [CAS 1802678-42-7]
|
|
COVID-19-immunoregulation
|
|
HY-104021-10mg
|
MedChemexpress LLC
|
GSK840 [CAS 2361146-30-5]
|
|
COVID-19-immunoregulation
|
|
HY-104021-100mg
|
MedChemexpress LLC
|
GSK840 [CAS 2361146-30-5]
|
|
COVID-19-immunoregulation
|
|
HY-104021-5mg
|
MedChemexpress LLC
|
GSK840 [CAS 2361146-30-5]
|
|
COVID-19-immunoregulation
|
|
HY-104021-50mg
|
MedChemexpress LLC
|
GSK840 [CAS 2361146-30-5]
|
|
COVID-19-immunoregulation
|
|
HY-10439-10mg
|
MedChemexpress LLC
|
HPGDS inhibitor 1 [CAS 1033836-12-2]
|
|
COVID-19-immunoregulation
|
|
HY-10439-100mg
|
MedChemexpress LLC
|
HPGDS inhibitor 1 [CAS 1033836-12-2]
|
|
COVID-19-immunoregulation
|
|
HY-10439-5mg
|
MedChemexpress LLC
|
HPGDS inhibitor 1 [CAS 1033836-12-2]
|
|
COVID-19-immunoregulation
|
|
HY-10439-50mg
|
MedChemexpress LLC
|
HPGDS inhibitor 1 [CAS 1033836-12-2]
|
|
COVID-19-immunoregulation
|
|
HY-109091-10mg
|
MedChemexpress LLC
|
Lanraplenib [CAS 1800046-95-0]
|
|
COVID-19-immunoregulation
|
|
HY-109091-100mg
|
MedChemexpress LLC
|
Lanraplenib [CAS 1800046-95-0]
|
|
COVID-19-immunoregulation
|
|
HY-109091-5mg
|
MedChemexpress LLC
|
Lanraplenib [CAS 1800046-95-0]
|
|
COVID-19-immunoregulation
|
|
HY-109091-50mg
|
MedChemexpress LLC
|
Lanraplenib [CAS 1800046-95-0]
|
|
COVID-19-immunoregulation
|
|